Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Nov;10 Suppl 2(Suppl 2):S48-S53.
doi: 10.1002/sctm.20-0517.

Therapeutic use of red blood cells and platelets derived from human cord blood stem cells

Xiaoyan Xie  1   2 , Hailei Yao  1   2 , Xiaoyan Han  3 , Wen Yue  1   2 , Xuetao Pei  1   2
Affiliations
Review

Therapeutic use of red blood cells and platelets derived from human cord blood stem cells

Xiaoyan Xie et al. Stem Cells Transl Med. 2021 Nov.

Abstract

Red blood cells (RBCs) and platelets derived from stem cells are possible solutions to the increasing demand for blood transfusion. Based on the availability of stem cells, their relatively defined differentiation mechanisms, and the massive exploration of induction systems, the generation of RBCs or platelets in vitro from cord blood hematopoietic stem/progenitor cells (CB-HSPCs) has potential for clinical applications. However, information on the clinical translation of stem cell-derived RBCs and platelets in the literature and at the ClinicalTrials.gov website is very limited. The only clinical trial on cultured RBCs, which aimed to assess the lifespan of RBCs cultured in vivo, was reported by Luc Douay and colleagues. Of note, the cultured RBCs they used were derived from autologous peripheral blood HSPCs, and no cultured platelets have been applied clinically to date. However, CB-HSPC-derived megakaryocytes, platelet precursors, have been used in the treatment of thrombocytopenia. A successful phase I trial was reported, followed by phase II and III clinical trials conducted in China. In this review, the gap between the many basic studies and limited clinical trials on stem cell-derived RBCs and platelets is summarized. The possible reasons and solutions for this gap are discussed. Further technological improvements for blood cell expansion and maturation ex vivo and the establishment of biological standards for stem cell derivatives might help to facilitate the therapeutic applications of cultured RBCs and platelets derived from CB-HSPCs in the near future.

Keywords: clinical translation; cord blood hematopoietic stem/progenitor cells; differentiation; megakaryocytes; platelets; red blood cells.

PubMed Disclaimer

Conflict of interest statement

The authors declared no potential conflicts of interest.

References

    1. Roberts N, James S, Delaney M, et al. The global need and availability of blood products: a modelling study. Lancet Haematol. 2019;6(12):e606‐e615. - PubMed
    1. Suddock JT, Crookston KP. Transfusion Reactions. Treasure Island, FL: StatPearls Publishing; 2021. - PubMed
    1. Mayani H, Lansdorp PM. Biology of human umbilical cord blood‐derived hematopoietic stem/progenitor cells. Stem Cells. 1998;16(3):153‐165. - PubMed
    1. Neildez‐Nguyen TM, Wajcman H, Marden MC, et al. Human erythroid cells produced ex vivo at large scale differentiate into red blood cells in vivo. Nat Biotechnol. 2002;20(5):467‐472. - PubMed
    1. Miharada K, Hiroyama T, Sudo K, et al. Efficient enucleation of erythroblasts differentiated in vitro from hematopoietic stem and progenitor cells. Nat Biotechnol. 2006;24(10):1255‐1256. - PubMed

Publication types